Register
Login:
Share:
Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis Watch Now

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Glaxosmithkline Share News (GSK)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Glaxosmithkline (GSK)


Share Price: 1,555.00Bid: 1,500.00Ask: 1,560.00Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 60.00Spread as %: 4.00%Open: 1,544.00High: 0.00Low: 0.00Yesterday’s Close: 1,555.00




Amicus's shares tank after Fabry disease drug fails trial

Wed, 19th Dec 2012 23:03

Dec 19 (Reuters) - Amicus Therapeutics said its experimental drug to treat
a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended trade on Wednesday.

The company is developing migalastat HCl in partnership with British drugmaker GlaxoSmithKline plc to treat Fabry disease, a genetic condition in which a type of fat gets deposited in human tissue, particularly in the kidneys.

The disease is caused by the body's inability to produce the enzyme that helps breaks down the fat.

The six-month study found that 13 out of the 32 patients who were put on migalastat HCl reported a reduction of 50 percent or more in the fat deposits in their kidneys, compared to 9 of the 32 in the group that was given a placebo.

'This difference did not achieve statistical significance according to the pre-specified primary endpoint analysis,' the company said.

Amicus said it expects to report results from 12 months of treatment in the first half of 2013, after which it plans to meet with the FDA to discuss a U.S. 'approval pathway.'

Fabry disease affects about 5,000 to 10,000 people worldwide and is believed to cause pain, kidney failure and increased risk of heart attack and stroke, according to the company.

Amicus shares closed at $5.77 on Wednesday on the Nasdaq, but fell as low as $2.80 after the bell.



(Reporting by Prateek Kumar and Zeba Siddiqui; Editing by Sreejiraj Eluvangal) Keywords: AMICUS STUDY FABRYDISEASE

(prateek.kumar@thomsonreuters.com)(within U.S. +1 646 223 8780, outside U.S. +91 80 4135 5800)(Reuters Messaging: prateek.kumar.thomsonreuters.com@reuters.net)

COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.






Trade rhetoric weighs on European shares

(For a live blog on European stocks, type LIVE/ in an Eikon news window)May 17 (Reuters) - European shares dropped on Friday after three days of gains
[17 May '19 08:03]

Ex-divs to take 23.6 points off FTSE 100 on May 16

MILAN, May 13 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the lates
[13 May '19 09:55]

UK regulator investigates China's state broadcaster for airing TV confession

LONDON, May 8 (Reuters) - Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aire
[8 May '19 15:14]

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 (Reuters) - British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc i
[4 May '19 17:24]

UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study

(Adds background on market opportunity)May 2 (Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met
[2 May '19 18:41]

UPDATE 4-GSK sees shingles vaccine sales rising, as free cash flow concerns weigh

(Adds details on respiratory drugs performance)* Vaccines unit sales surge 20 percent, led by Shingrix* Shingrix sales to be "significantly" more than
[1 May '19 12:29]

UPDATE 2-Oil firms, exporters drag FTSE 100, while Sainsbury's, LSE outshine

* FTSE 100 down 0.4 pct* FTSE 250 down 0.1 pct* Oil majors, international firms weigh* Sainsbury's jumps on profit beat* Lloyds gains on hopes of more
[1 May '19 09:39]

UPDATE 2-Oil heavyweights, exporters guide FTSE 100 close to 7-month high

* FTSE 100 up 0.9 pct* FTSE 250 up 0.3 pct* Oil majors take main index higher* Oil price surge hits airlines* Softer sterling boosts exporter stocks*
[23 Apr '19 09:48]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.